bluebird bio
BLUE
BLUE was delisted on the 30th of May, 2025.
193 hedge funds and large institutions have $2.53B invested in bluebird bio in 2015 Q4 according to their latest regulatory filings, with 44 funds opening new positions, 86 increasing their positions, 49 reducing their positions, and 41 closing their positions.
76% more repeat investments, than reductions
Existing positions increased: 86 | Existing positions reduced: 49
7% more first-time investments, than exits
New positions opened: 44 | Existing positions closed: 41
1% more funds holding
Funds holding: 192 → 193 (+1)
19% less capital invested
Capital invested by funds: $3.12B → $2.53B (-$591M)
25% less call options, than puts
Call options by funds: $39.2M | Put options by funds: $52M
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
+$58.8M |
| 2 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$51.5M |
| 3 |
Jennison Associates
New York
|
+$38.8M |
| 4 |
State Street
Boston,
Massachusetts
|
+$26M |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
+$21.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Viking Global Investors
Stamford,
Connecticut
|
-$52.7M |
| 2 |
DM
Deerfield Management
New York
|
-$41.3M |
| 3 |
First Trust Advisors
Wheaton,
Illinois
|
-$28.2M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$19.9M |
| 5 |
O
OrbiMed
New York
|
-$19.1M |
BLUE Hedge Fund Activity: Q4 2015 in Review
193 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in bluebird bio (BLUE) for Q4 2015, worth a combined $2.53B — down 19% from $3.12B a quarter earlier.
Buyers outnumbered sellers: 44 funds opened new BLUE positions and 41 closed out — a net gain of 3 holders — while 86 added to existing stakes and 49 trimmed.
The largest buyer was Capital World Investors, adding an estimated $58.8M. The largest seller was Viking Global Investors, exiting entirely with an estimated $52.7M sold.
- 193 institutional investors held bluebird bio (BLUE) as of Q4 2015, up from 192 in Q3 2015.
- Funds reported $2.53B of bluebird bio stock for Q4 2015, down 19% quarter-over-quarter.
- 44 funds opened new bluebird bio positions in Q4 2015 and 41 closed out, a net change of +3 holders.
- The largest bluebird bio buyer in Q4 2015 was Capital World Investors, an estimated $58.8M added.
- The largest bluebird bio seller in Q4 2015 was Viking Global Investors, an estimated $52.7M sold.
Based on aggregated 13F filings for Q4 2015.